Frazier Life Sciences Management, L.P. Vectiv Bio Holding Ag Transaction History

Frazier Life Sciences Management, L.P.

  • $1.86 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$7.34 - $9.15 $137,984 - $172,010
18,799 Added 1.41%
1,352,199 $11.5 Million
Q4 2022

Feb 03, 2023
BUY
$7.79 - $8.98 $10.4 Million - $12 Million
1,333,400 New
1,333,400 $11.5 Million

Others Institutions Holding VECT

# of Institutions
1
Shares Held
510K
Call Options Held
0
Put Options Held
0
View Full List

About VectivBio Holding AG

VECT Quotes by TradingView
  • Ticker VECT
  • Exchange NASDAQ
  • Description
  • VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with sho...
More about VECT
Track This Portfolio

Track Frazier Life Sciences Management, L.P. Portfolio

Follow Frazier Life Sciences Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Life Sciences Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Frazier Life Sciences Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email